ERESPAL SYRUP BOTTLE 150ML

Indications

Diseases of the upper and lower respiratory tract:

- rhinopharyngitis and laryngitis;

- tracheobronchitis;

- bronchitis (with or without chronic respiratory failure);

- bronchial asthma (as part of complex therapy);

- respiratory symptoms (cough, hoarseness, sore throat) for measles, whooping cough, flu;

- Infectious diseases of the respiratory tract, accompanied by cough, when shown standard antibiotic therapy.

Otitis and sinusitis of various etiologies.

Dosage and administration

Adults and teenagers the drug is prescribed in 3-6 tablespoons (45-90 ml) / day, taken before meals.

Children from 2 years the drug is prescribed at the rate of 4 mg / kg body weight / day. Children weighing up to 10 kg - 2-4 teaspoons (10-20 ml) / day, you can add to the bottle with food. Children weighing more than 10 kg - 2-4 tablespoons (30-60 ml) / day, taken before meals.

Syrup before use should be shaken.

1 tablespoon (15 ml) contains 30 mg of fenspirid hydrochloride and 9 g of sucrose.

1 teaspoon (5 ml) contains 10 mg of fenspirid hydrochloride and 3 g of sucrose.

The duration of treatment is determined by the doctor.

Adverse effects

The most frequent adverse reactions to the drug Erespal ® observed by the digestive system.

The frequency of adverse reactions that may occur during therapy,given in the form of the following gradation: very often (> 1/10); often (> 1/100, <1/10); infrequently (> 1/1000, <1/100); rarely (> 1/10 000, <1/1000); very rarely (<1/10 000); frequency not set (frequency cannot be calculated from available data).

Cardiovascular: rarely - moderate tachycardia, the severity of which decreases with a decrease in the dose of the drug; unspecified frequency * - a sensation of heartbeat, hypotension, possibly associated with tachycardia.

Gastrointestinal: often - gastrointestinal disorders, nausea, epigastric pain; Unknown frequency * - diarrhea, vomiting.

From the side of the central nervous system: rarely - drowsiness; frequency not set * - dizziness.

From the skin and subcutaneous fat: rarely - erythema, rash, urticaria, angioedema, fixed erythema pigmentosa; Unknown frequency * - pruritus, toxic epidermal necrolysis, Stevens-Johnson syndrome.

Common disorders: Unset frequency * - asthenia, fatigue.

* Post-registration application data.

The patient should be informed about the need to inform the doctor about any, including adverse reactions not mentioned above, as well as changes in laboratory parameters during therapy with Erespal®.

Contraindications

- children's age up to 2 years;

- hypersensitivity to the active substance and / or any of the components of the drug.

Carefully: patients with fructose intolerance, glucose-galactose malabsorption, sucrase / isomaltase deficiency (due to the presence of sucrose in the composition), patients with diabetes mellitus.

Use during pregnancy and lactation

Data on the use of the drug Erespal® pregnant women are absent or limited. Use of the drug during pregnancy is not recommended.

Therapy with fenspiride is not a basis for abortion of the onset of pregnancy.

Do not use Erespal® during breastfeeding due to the lack of data on the penetration of fenspiride into breast milk.

Use in children

Contraindicated in children under 2 years.

Special notes

The preparation in the form of a syrup includes parabens (parahydroxybenzoates), as a result, taking this drug can provoke the development of allergic reactions, including deferred.

When prescribing the drug to patients with diabetes, it is necessary to take into account that Erespal® syrup contains sucrose (1 teaspoon - 3 g sucrose = 0.3 XE; 1 tablespoon - 9 g sucrose = 0.9 XE).

Influence on ability to drive motor transport and control mechanisms

Studies on the effect of the drug Erespal® the ability to drive and work with mechanisms was not carried out. Patients should be aware of the possible development of drowsiness while taking the drug Erespal®, especially at the beginning of therapy or when combined with alcohol intake, and should be careful when driving vehicles and when performing work that requires high speed psychomotor reactions.

Overdosage

In case of overdose of the drug (there are cases of overdose when taking the drug in a dose of more than 2320 mg), the patient should immediately seek medical help.

Symptoms: drowsiness or agitation, nausea, vomiting, sinus tachycardia.

Treatment: gastric lavage, ECG monitoring, maintenance of vital body functions.

Drug interaction

Special studies on the interaction of fenspiride with other drugs have been conducted.

Due to the possible sedative effect when taking histamine H blockers1-receptors do not recommend the use of the drug Erespal® syrup in combination with drugs with a sedative effect, or in conjunction with alcohol.

Terms and conditions of storage

The drug should be kept out of the reach of children. Special storage conditions are not required.